| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net loss | -31,333 | -12,725 | -40,455 | -29,524 |
| Comprehensive loss | -31,333 | -12,725 | -40,455 | -29,524 |
| Net loss per common share - basic (in dollars per share) | -0.16 | -0.06 | -0.21 | -0.15 |
| Net loss per common share - diluted (in dollars per share) | -0.16 | -0.06 | -0.21 | -0.15 |
| Weighted-average shares outstanding - basic (in shares) | 200,736,136 | 197,546,239 | 196,127,948 | 194,930,830 |
| Weighted-average shares outstanding - diluted (in shares) | 200,736,136 | 197,546,239 | 196,127,948 | 194,930,830 |
Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc. (ESPR)